🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Opioid Use Disorder

Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression NCT05058287Phase 31 site📍 New York Hospital for Special Surgery, New York · Tests: Depo-Medrol 40Mg/Ml Suspension for Injection, Placebo Imaging CRF X NOP Interactions in CUD NCT05008146EARLY Phase 11 site📍 Pittsburgh Rajesh Narendran · Tests: Baseline [C-11]NOP-1A PET Scan, Hydrocortisone, Post-hydrocortisone [C-11]NOP-1A PET Scan Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment NCT06032559Phase 32 sites📍 New Brunswick📍 Salt Lake City Rutgers, The State University of New Jersey · Tests: MORE, SMP, TAU Pain Management Teams Using Whole Health to Optimize Function and Safety in Veterans: The TEAMWORK Trial NCT07149870NA5 sites📍 Birmingham📍 Little Rock📍 Aurora VA Office of Research and Development · Tests: Pain Management Team + Whole Health Coach (PMT-WHC), Pain Management Team-Usual Care (PMT-UC) Mindfulness in Endometrial and Cervical Cancer NCT04512144NA1 site📍 St Louis St. Louis University · Tests: Headspace Smartphone Application Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Disorder Treatment NCT07197801NA1 site📍 Danville Geisinger Clinic · Tests: Peer recovery support to enhance patient engagement in medication for opioid use disorder treatment Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment NCT06323837Phase 21 site📍 Spokane Washington State University · Tests: Mirtazapine, Placebo Teaching Health Resilience in a Hospital Setting: A Peer-led Intervention NCT06843213NA3 sites📍 Pittsburgh📍 Pittsburgh📍 Pittsburgh University of Pennsylvania · Tests: Peer Intervention, Enhanced Usual Care Mindfulness Texting for Medication Adherence and Chronic Pain Management NCT07711795NA1 site📍 Albuquerque University of New Mexico · Tests: Mindfulness text messages Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes NCT03923374n/a1 site📍 Pittsburgh Senthil Sadhasivam · Tests: Subutex / Buprenorphine, Fetal & Neonatal MRI, DNA/Genetic/Pharmacokenetic Blood Draws Brief Digitally-Enhanced Intervention for Reducing Alcohol Use During MOUD NCT06718491NA1 site📍 Columbus Ohio State University · Tests: Managing Physical Reactions to Overwhelming Emotions (IMPROVE), Health Education Training (HET) MATAspire: Mental Health Awareness Tailored App for Substance Prevention and Integrated Resilience Education NCT06553196NA1 site📍 Northridge California State University, Northridge · Tests: MATAspire Web-app CARES (Comprehensive Analgesic, Recovery, and Education Support) for Surgery Trial NCT06027099Phase 34 sites📍 Stanford📍 Kansas City📍 Boston Stanford University · Tests: Tizanidine, MI-Opioid Taper, Placebo, Enhanced Usual Care Evaluation of an Opioid Stewardship Program in Non-Cancer Patients NCT07102446NA1 site📍 Seoul Korea University Guro Hospital · Tests: Opioid Stewardship Program A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) NCT06655883Phase 313 sites📍 Garden Grove📍 New Haven📍 Bradenton Merck Sharp & Dohme LLC · Tests: Suvorexant, Placebo Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects NCT06981195Phase 21 site📍 Richmond Virginia Commonwealth University · Tests: Placebo, Lemborexant 10 MG Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder NCT06067737Phase 21 site📍 Baltimore Johns Hopkins University · Tests: Psilocybin, Psilocybin Clinical Decision Support to Increase Use of Medications for Opioid Use Disorder NCT06526286n/a1 site📍 Aurora University of Colorado, Denver · Tests: Medications for Opioid Use Disorder Pathway Clinical Decision Support (CDS) PRIDE III Prison Interventions and HIV Prevention Collaboration NCT06962033NA5 sites📍 New Haven📍 Tbilisi📍 Bishkek Yale University · Tests: Opioid Agonist Therapy Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses NCT07631598NA8 sites📍 Los Angeles📍 Washington D.C.📍 Baton Rouge Montefiore Medical Center · Tests: Standard of Care Referral, Low Threshold Buprenorphine A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use NCT06726200EARLY Phase 11 site📍 New York Rachel R. Luba · Tests: Buprenorphine + naloxone (Suboxone), Buprenorphine Injection Real-time Opioid Study NCT07768007NA1 site📍 New Haven Yale University · Tests: real-time functional magnetic resonance imaging (rt-fMRI) neurofeedback Evaluating Pain Control Strategies in Postpartum Patients on Opioid Use Disorder Medications. NCT06617949EARLY Phase 12 sites📍 Milwaukee📍 Milwaukee Medical College of Wisconsin · Tests: Regional Anesthesia, Hydromorphone Patient Controlled Analgelsic, Epidural local anesthetic infusion Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data NCT06768814NA1 site📍 Seattle University of Washington · Tests: Sub-acute stabilization Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder NCT06487533n/a2 sites📍 Center City📍 Columbus Spark Biomedical, Inc. · Tests: EmbracePlus Smartwatch, Corti Sensor Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention NCT05973838NA4 sites📍 Washington D.C.📍 Baltimore📍 College Park University of Maryland, College Park · Tests: Peer-Delivered Behavioral Activation ("Peer Activate") Measuring Acute Drug Demand in Humans NCT05829655EARLY Phase 11 site📍 Baltimore University of Maryland, Baltimore · Tests: Drug A (Blinded Drug), Drug B (Blinded Drug), Drug C (Blinded Drug), Drug D (Blinded Drug), Suvorexant (20mg/day) Cannabis and Opioid Use Disorder NCT05729932Phase 11 site📍 Lexington Shanna Babalonis, PhD · Tests: Inhaled vaporized cannabis, Intransal opioid Imaging CRF X NOP Interactions in Alcohol Use Disorder NCT07612631EARLY Phase 11 site📍 Pittsburgh Rajesh Narendran · Tests: Baseline [C-11]NOP-1A PET scan, Hydrocortisone, Post-hydrocortisone [C-11]NOP-1A PET scan Ketamine Assisted Psychotherapy for Opioid Use Disorder NCT04892251Phase 1, Phase 21 site📍 Salt Lake City University of Utah · Tests: MORE+KAP, MORE
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy